Clinical trials: Alzheimer Dementia
Alzheimer Disease
Open-label Extension for Phase 3 Clinical Trials of Simufilam
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
- Trial name
- NCT05575076
- Testing
- Simufilam
- Where
- 134 sites in United States, Australia and 3 more
- Volunteers
- 1,081 people
- Sponsor
- Cassava Sciences, Inc.
Dementia, Dementia, Vascular
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
The goal of this clinical trial is to improve communication among clinicians, patients with memory problems, and their family members.
- Conditions
- Dementia, Dementia, Vascular, Mixed Dementias, Alzheimer Disease
- Trial name
- PICSI-M (NCT05596760)
- Testing
- Jumpstart Guide
- Where
- 3 sites in United States
- Volunteers
- 1,802 people
- Sponsor
- University of Washington
Alzheimer's Disease (AD)
Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease
The primary objective of this exploratory imaging study is to further characterize [18F]T807, an investigational PET radioligand for imaging Tau (thought to be a downstream biomarker indicative of neurodegeneration in conditions…
- Trial name
- NCT02370524
- Testing
- [18F]T807
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Molecular NeuroImaging
Alzheimer Disease
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD).
- Trial name
- NCT06297590
- Testing
- LY3954068, Flortaucipir F18
- Where
- 10 sites in United States, Japan and 1 more
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Alzheimer Disease
Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers
This study aims to evaluate the therapeutic efficacy of Lecanemab in patients with Alzheimer's disease. The researchers will use a novel detection method based on mesoporous gold electrode surface-enhanced…
- Trial name
- ECL-Lecanemab (NCT07688460)
- Testing
- Lecanemab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Alzheimer's Disease
Deep Brain Stimulation for the Treatment of Alzheimer's Disease
The purpose of this clinical study is to investigate the safety and efficacy of deep brain stimulation (DBS)as a treatment option for patients with cognitive, behavioral, and functional disability of Alzheimer's disease.
- Trial name
- NCT01559220
- Testing
- Deep Brain Stimulation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Ali Rezai, MD
Dementia, Alzheimer Type
Technology Intervention to Support Caregiving for Alzheimer's Disease (I-CARE)
The specific aims of this study are 1) to test the trial and intervention feasibility of Brain Care Notes (BCN) app, 2) To estimate the effect size of BCN on reducing informal caregiver burden at 6 months, and 3) To estimate the…
- Trial name
- I-CARE (NCT03119259)
- Testing
- ABC Clinical Program, BCN
- Where
- 2 sites in United States
- Volunteers
- 53 people
- Sponsor
- Indiana University
Physical Therapy
Trunk Control, Balance, Gait, Functional Mobility and Fear of Falling in People With Alzheimer's Disease
The purposes of this study were to investigate the relationship between trunk control and balance, gait, functional mobility, and fear of falling in people with Alzheimer's disease and to compare trunk control, balance, gait…
- Trial name
- NCT05576688
- Testing
- Balance, Trunk control, Gait
- Where
- Turkey (Türkiye)
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ankara Yildirim Beyazıt University
Alzheimer's Disease, Mild Cognitive Impairment
A PET Study of the Effects of p38 MAP Kinase Inhibitor, VX-745, on Amyloid Plaque Load in Alzheimer's Disease (AD)
This study will assess the effects of administration of VX-745 for 12 weeks on amyloid plaque burden in Alzheimer's disease (AD).
- Trial name
- NCT02423122
- Testing
- VX-745
- Where
- Netherlands
- Volunteers
- 16 people
- Sponsor
- EIP Pharma Inc
Mild to Moderate Alzheimer's Disease
Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease
A double-blinded, randomized, placebo-controlled study will be performed to evaluate the efficacy and safety of treating AR1001 in patients with mild to moderate Alzheimer's disease for 26 weeks.
- Trial name
- NCT03625622
- Testing
- AR1001
- Where
- 21 sites in United States
- Volunteers
- 210 people
- Sponsor
- AriBio Co., Ltd.
Alzheimer Disease
Transmagnetic Stimulation Pilot in Early Stage Alzheimer's Disease
Alzheimer's disease (AD) is a progressive neurodegenerative condition affecting 6.2 million individuals in the United States, resulting in an annual cost of care of $305 billion.
- Trial name
- NCT05292222
- Testing
- Intermittent theta burst stimulation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- HealthPartners Institute
Alzheimer Disease
Cerebrolysin Compared to Donepezil in Patients With Mild to Moderate Dementia of Alzheimer's Type (DAT)
The objective of this trial is the global risk-benefit assessment of Cerebrolysin as compared to donepezil in patients with mild to moderate dementia of Alzheimer's Type (DAT).
- Trial name
- DAT (NCT01822951)
- Testing
- Cerebrolysin, Donepezil
- Where
- Austria
- Sponsor
- Ever Neuro Pharma GmbH
Mild to Moderate Alzheimer's Disease
Testing the Safety and Preliminary Efficacy of the New Drug ORY-2001 in Mild to Moderate Alzheimer's Disease
This is a Phase IIa study assessing the safety, tolerability and preliminary efficacy of ORY-2001 in mild to moderate Alzheimer's Disease patients.
- Trial name
- ETHERAL-US (NCT03867253)
- Testing
- ORY-2001 Low dose, ORY-2001 High dose
- Where
- 4 sites in United States
- Volunteers
- 24 people
- Sponsor
- Oryzon Genomics S.A.
Healthy Individuals (Controls), Parkinson Disease
Motor Learning in Health and Movement Disorders: Role of Physical Activity and Advanced Devices
The goal of this clinical trial is to investigate motor responses in healthy subjects and patients with movement disorders, brain and spinal cord injury, neuromuscular diseases, or cardiovascular diseases.
- Conditions
- Healthy Individuals (Controls), Parkinson Disease, Multiple Sclerosis, Alzheimer Disease
- Trial name
- Allena-mente (NCT07066137)
- Testing
- CAREN, Control group
- Where
- Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
Alzheimer's Disease
Omental Transposition Surgery for Mild Alzheimer's Disease
This study is a prospective, single arm, non-randomized, interventional study to evaluate the safety and effectiveness of Omental transposition (OT) in subjects with early stage AD.
- Trial name
- NCT02349191
- Testing
- Omental transposition for mild Alzheimers disease
- Volunteers
- 25 people
- Sponsor
- Bariatric Medicine Institute, Salt Lake City, UT
Alzheimer's Disease
Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.
- Trial name
- NCT05227118
- Testing
- Elpipodect
- Where
- 8 sites in United States
- Volunteers
- 29 people
- Sponsor
- Merck Sharp & Dohme LLC
Alzheimer Disease
Melatonin in Alzheimer's Disease: Effect on Disease Progression and Epileptiform Activity.
This is a long-term, prospective, observational study to investigate and compare the levels and rhythm of melatonin in patients with AD dementia, mild cognitive impairment due to AD and healthy volunteers.
- Trial name
- MADE (NCT04522960)
- Testing
- MEG+hdEEG+MRI
- Where
- Belgium
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Agitation in Patients With Dementia of the Alzheimer's Type
Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in participants with dementia of the Alzheimer's type.
- Trial name
- NCT03393520
- Testing
- AVP-786
- Where
- 211 sites in United States, Australia and 9 more
- Volunteers
- 601 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Dementia, Alzheimer Disease
Volunteers Adding Life in Dementia
The objectives of our project are to: 1.) Develop a training program and manual for volunteers to implement evidence-based, non-pharmacological interventions for neuropsychiatric symptoms (NPS) of dementia in long-term care (LTC)…
- Conditions
- Dementia, Alzheimer Disease, Behavior
- Trial name
- VALID (NCT01646723)
- Testing
- Volunteers Adding Life in Dementia (VALID) Program
- Where
- Canada
- Volunteers
- 75 people
- Sponsor
- Queen's University
Alzheimer s Disease, MCI Conversion to Dementia
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
- Conditions
- Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- Trial name
- NCT07701161
- Where
- 5 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Neurogen Biomarking LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.